Hydrocortisone 17-butyrate
Hydrocortisone 17-butyrate structure
|
Common Name | Hydrocortisone 17-butyrate | ||
|---|---|---|---|---|
| CAS Number | 13609-67-1 | Molecular Weight | 432.550 | |
| Density | 1.2±0.1 g/cm3 | Boiling Point | 585.6±50.0 °C at 760 mmHg | |
| Molecular Formula | C25H36O6 | Melting Point | 212 °C | |
| MSDS | Chinese USA | Flash Point | 194.0±23.6 °C | |
|
Convenient QSAR model for predicting the complexation of structurally diverse compounds with β-cyclodextrins
Bioorg. Med. Chem. 17 , 896-904, (2009) This paper reports a QSAR study for predicting the complexation of a large and heterogeneous variety of substances (233 organic compounds) with beta-cyclodextrins (beta-CDs). Several different theoretical molecular descriptors, calculated solely from the mole... |
|
|
Synergistic topical application of salt-processed Phellodendron amurense and Sanguisorba officinalis Linne alleviates atopic dermatitis symptoms by reducing levels of immunoglobulin E and pro-inflammatory cytokines in NC/Nga mice.
Mol. Med. Report. 12 , 7657-64, (2015) Atopic dermatitis is a chronic inflammatory skin disease, and salt-processed Phellodendron amurense (CPE) and Sanguisorba officinalis Linne (SOE) are widely used as anti-inflammatory agents in Asia. Therefore, the present study investigated the efficacy of CP... |
|
|
Statistical design for formulation optimization of hydrocortisone butyrate-loaded PLGA nanoparticles.
AAPS PharmSciTech 15(3) , 569-87, (2014) The aim of this investigation was to develop hydrocortisone butyrate (HB)-loaded poly(D,L-lactic-co-glycolic acid) (PLGA) nanoparticles (NP) with ideal encapsulation efficiency (EE), particle size, and drug loading (DL) under emulsion solvent evaporation tech... |
|
|
[Hydrocortisone 17-butyrate (Locoid), a thirty-year ongoing innovative drug].
Rev. Med. Liege. 61(2) , 128-30, (2006) Since half a century, dermocorticoids represent worthy compounds in dermatological therapy. About thirty years ago, hydrocortisone 17-butyrate was introduced on the Belgian market. This compound combines good efficiency and reduced risk of side effects. Its t... |
|
|
Corticosteroid solubility and lipid polarity control release from solid lipid nanoparticles.
Int. J. Pharm. 390(1) , 53-60, (2010) Solid lipid nanoparticles (SLN) show promise as a drug delivery system for skin administration. The solid state of the lipid particle enables efficient drug encapsulation and controlled drug release. The present study addresses the influence of lipid composit... |
|
|
Systematized contact dermatitis and montelukast in an atopic boy.
Pediatr. Dermatol. 26(6) , 739-43, (2009) Upon ingestion, the artificial sweetener, aspartame is metabolized to formaldehyde in the body and has been reportedly associated with systemic contact dermatitis in patients exquisitely sensitive to formaldehyde. We present a case of a 9-year-old Caucasian b... |
|
|
Evaluation of adrenal suppression of a lipid enhanced, topical emollient cream formulation of hydrocortisone butyrate 0.1% in treating children with atopic dermatitis.
Pediatr. Dermatol. 24(1) , 81-4, (2007) Corticosteroids are currently the first line of treatment for patients with atopic dermatitis. In the pediatric population however, the potential impact of adrenal suppression is always an important safety concern. Twenty boys and girls, 5-12 years of age, wi... |
|
|
Expression of adhesion molecules in atopic dermatitis is reduced by tacrolimus, but not by hydrocortisone butyrate: a randomized immunohistochemical study.
Clin. Exp. Dermatol. 31(6) , 813-7, (2006) Topical tacrolimus represents an effective and well-tolerated treatment for atopic dermatitis (AD). Its known effects include reduced production of proinflammatory cytokines and reduced chemokine gradient. We performed lesional skin biopsies on adult patients... |
|
|
Acquired Blaschkoid dermatitis.
Indian J. Dermatol. Venereol. Leprol. 73(6) , 415-6, (2007) Acquired Blaschkoid dermatitis characterised by unilateral relapsing inflammatory disease along the lines of Blaschko. A 40-year-old Indian male presented with unilateral erythematous, itchy grouped papules on the left side of the chest, abdomen, back and lef... |
|
|
Hydrocortisone butyrate 0.1% lotion in the treatment of atopic dermatitis in pediatric subjects.
Journal. of. Drugs in. Dermatology. 7(3) , 266-71, (2008) Hydrocortisone butyrate (HCB) is currently marketed as a cream, ointment, and solution. A new lotion formulation of hydrocortisone butyrate 0.1% (Locoid lotion) has been developed and evaluated.The objective of this study was to evaluate the efficacy and safe... |